Evercore ISI Group Maintains Outperform on Ultragenyx Pharmaceutical, Lowers Price Target to $37

Ultragenyx Pharmaceutical, Inc. -1.70%

Ultragenyx Pharmaceutical, Inc.

RARE

21.34

-1.70%

Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ: RARE) with a Outperform and lowers the price target from $39 to $37.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via